Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation highlights findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics, underscoring the importance of tissue-level drug distribution in determining toxicity profiles.
Everolimus is an mTOR inhibitor used in oncology and immunosuppression, but its clinical use is limited by systemic toxicity. Sapu Nano's research focuses on understanding how drug accumulation in specific tissues influences adverse effects, which could lead to improved delivery strategies. The company is developing intravenous and nanoparticle-based formulations to enhance therapeutic index and reduce off-target toxicity.
The presentation at SOT 2026 supports Sapu Nano's broader mission to advance next-generation nanomedicine platforms. According to the press release, the data could unlock new clinical potential for established therapeutics by optimizing drug delivery. For more details, the full press release is available at https://ibn.fm/kZzE3.
Oncotelic, formerly known as Mateon Therapeutics, focuses on oncology drug development with a special emphasis on rare pediatric cancers. The company has rare pediatric designations for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia through OXi 4503. Oncotelic also acquired PointR Data Inc. to build an AI-driven biotechnology company and AL-101 for intranasal delivery of apomorphine, targeting Parkinson's disease and other conditions.
Investors can find the latest news and updates on OTLC at the company’s newsroom: https://ibn.fm/OTLC.
